Finally, PAK1 disruption has also been shown to normalize behavioral changes in the Fragile X model of autism (Dolan et al., 2013; Hayashi et al., 2007), which parallels recent behavioral work similarly demonstrating that administration of AEA, but not 2-AG, hydrolysis inhibitors, can normalize some of the same behavioral deficits seen in Fragile X mice (Qin et al., 2015). The gene discussed is PAK1; the disease is autism.